Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2017

View Archived Issues

Mitsubishi Tanabe Pharma offers overview of first quarter of fiscal 2017

Pfizer reflects on milestones of second quarter 2017

MiMedx initiates phase III study of AmnioFix Injectable following phase IIb results

Pellficure Pharmaceuticals begins enrollment in phase I trial of PCUR-101 in metastatic CRPR

Proclara Biosciences' GAIM-Ig fusion NPT-189 blocks assembly of amyloid aggregates

Intec reports phase I results for AP-CBD/THC

Vaccibody files German clinical trial application for cancer neoantigen vaccine VB10.NEO

FDA approves Mavyret for HCV

Cormedix provides update on ongoing phase III study of Neutrolin

Novel peptide-based viral inactivator shows promise as treatment against ZIKV in vivo

EMA announces business continuity plan to prepare for U.K.'s withdrawal from the E.U.

Sentinel Oncology receives Innovate UK grant to study SOL-784

Bristol-Myers Squibb to acquire IFM Therapeutics

FDA advisory committee recommends approval of Xeljanz for psoriatic arthritis

ANGPTL3 antagonism is associated with reduced risk of atherosclerotic cardiovascular disease

Takeda and Molecular Templates establish new oncology drug discovery collaboration

Novel susceptibility variants for Alzheimer's disease identified in Chinese subjects

Realm Therapeutics submits IND for PR-013 for allergic conjunctivitis

EpiVax receives funding to support development of personalized cancer vaccines

Oxeia acquires rights to SUN-11031 from KineMed

FDA approves Vyxeos for two types of AML

U.S. researchers patent antiparasitic compounds

Beth Israel Deaconess Medical Center discloses CRAC blockers

Janssen Pharmaceutica identifies MAP3K14 inhibitors

Sichuan Haisco Pharmaceutical divulges new antivirals

NIH researchers develop mouse model to track Zika virus transmission

Dolutegravir superior in combination with NRTIs for treating HIV-1 infection

FDA awards orphan drug designation to Applied Genetic Technologies' gene therapy candidate for XLRP

Portola resubmits AndexXa BLA

Dynavax updates status of Heplisav-B submission following FDA advisory committee meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...